GenDx

Exciting news: NGSgo-ProntoFLX is now available in 24-reaction kits, in addition to the existing 96-reaction format. 🧬

The new 24-reaction kits give you more flexibility when processing smaller sample numbers.

The 24-reaction format is now available for:
▶️ NGSgo-ProntoFLX HLA-A
▶️ NGSgo-ProntoFLX HLA-B
▶️ NGSgo-ProntoFLX HLA-DQA1, DQB1

NGSgo-ProntoFLX provides rapid, flexible, and accurate single-locus HLA typing on Oxford Nanopore Technologies (ONT) sequencing devices, with sequencing taking just 1 minute per locus.

For more information, visit our website
🔗 https://www.gendx.com/2026/10/ngsgo-prontoflx-now-available-also-in-24-reaction-kits/

Already packing for the ASHI meeting? Take your sneakers with you, because we will start our Wednesday, October 28, with a 5K Tulip Run! 👟🌷

As is tradition, you can join us for a walk or a run. Stop by booth #201 to pick up your T-shirt and learn more. All funds raised will go to a good cause.

🕡 6:30 AM – 8:00 AM
It's a great way to shake off conference fatigue and connect with fellow attendees before the sessions begin.

Let's meet at the 16th Annual CB & CDx Summit in Boston!

We are excited to announce that the GenDx Companion Diagnostics team will be in Boston for the 16th World Clinical Biomarkers & Companion Diagnostics Summit. We would be delighted to meet you at the conference and discuss how our HLA testing solutions can support your clinical trials and companion diagnostic development.

Don't miss the opportunity to join Erica Kremer-Groot and Jules Petit at the expert breakfast briefing, "HLA as a Companion Diagnostic Biomarker: What Does it Take to Make it Work in a Clinical Trial?"

Together with experts from Versiti Clinical Trial Solutions and ARC Regulatory, our team will join a candid conversation about the scientific, operational, and regulatory considerations involved in incorporating HLA testing into clinical trials and companion diagnostic strategies.

📅 October 7, 2026
🕖 7:00 AM
📍 The Westin Seaport, Marina Ballroom III, Boston, MA

To learn more, visit our website: https://www.gendx.com/2026/10/meet-gendx-at-the-16th-annual-cb-cdx-summit-in-boston/

We are introducing a new journal club webinar to critically appraise the latest publications and evidence in transplant surveillance.

In this inaugural kidney transplant session, we will review key studies published over the last couple of years, discuss their clinical relevance, and explore how recent findings may influence patient management and future research directions.

This session will be hosted by:
▶️ Valentina M. Zinna, PhD, Medical Science Liaison EMEA, Medical Affairs at GenDx
🕛 12:00 CEST (English) | 17:00 CEST (Spanish)
📅 October 21, 2026
💻 Online

Sessions will be held in English and, for the first time, in Spanish.

To learn more about the topic and register for the session, visit our website: 🔗 https://www.gendx.com/gendx_education/webinar-gendx-journal-club-whats-new-in-dd-cfdna-for-kidney-transplant-surveillance/

Our program for this year's ASHI Annual Meeting is here! We can't wait to connect with professionals from around the world in histocompatibility and transplant immunology.

📍 Palais des congrès de Montréal, QC, Canada
📅 October 26–30, 2026

Swipe through to see our full program 👉

We are happy to announce our upcoming Teaching Session!
Join us for training featuring our latest updates and innovations.

⏲️ 09:00 – 16:30
📅 October 26, 2026
📍Palais des congrès de Montréal, QC, Canada

In the morning, we will cover new product releases from the past year as well as new developments. In the afternoon, we will focus on interactive case studies using NGSengine.

Whether you use Illumina or Oxford Nanopore Technologies sequencing or apply a hybrid capture or long-range PCR-based HLA typing strategy, you will gain valuable insights.

🔗 To register, visit our website
https://www.gendx.com/gendx_education/teaching-session-october-26-2026/

Our new webinar season starts in September, and we are kicking it off with a topic we have been excited to share 👇

Mapping African HLA Diversity: High-Resolution Genotyping and Discovery of HLA-E*01:152

📅 September 9, 2026
⏲️ 12:00 CEST
📍 Online

Join us as we present two published studies from the AHRI Ndhlovu Lab, characterizing HLA variation across Eastern and Southern Africa.

➡️ The first analyzed HLA-A, HLA-B, and HLA-C data from 2,718 unrelated African participants from Kenya, Rwanda, Uganda, South Africa, and Zambia. This study showed that population-genetic analyses of allele and haplotype frequencies and Hellinger distance revealed variation between countries and ethnic groups.

➡️ The second communication identified the novel HLA-E*01:152 allele in 12 of 580 individuals genotyped across Zimbabwe, South Africa, Zambia, and Kenya. This allele was strongly associated with HLA-A*29:11.

Register here 👇
🔗 https://www.gendx.com/gendx_education/webinar-mapping-african-hla-diversity-high-resolution-genotyping-and-discovery-of-hla-e01152/

Why do some patients respond to immune checkpoint inhibitors and others don't?

In our latest post, we explore how a patient's HLA type may be associated with the response to immune checkpoint inhibitors.

It's the third post in our CDx blog post series on "Exploring HLA in tumors", where we previously introduced the central role of HLA molecules in tumor immunology and discussed how tumors can alter HLA pathways to evade immune detection and destruction.

🔗 Read it here:
https://www.gendx.com/2026/07/exploring-hla-in-tumors-the-role-of-hla-in-immune-checkpoint-inhibitor-therapy/

Exploring HLA in tumors: The role of HLA in immune checkpoint inhibitor therapy In this blog post, we explore how a patient's HLA type may associate with the efficacy of immune checkpoint inhibitors.

1,000 patients pre-screened for HLA-A for the ARTEMIA trial🥳

In collaboration with OSE Immunotherapeutics, the sponsor of the ARTEMIA trial, GenDx has reached a significant milestone: 1,000 patients have now been pre-screened using a test for high-resolution HLA-A*02 typing, which is currently under companion diagnostic development. One step closer to Non-Small Cell Lung Cancer (NSCLC) patients getting new options for treatment.

Developed and validated since 2023, our assay is based on our IVDR-registered devices, NGSgo®-AmpX v2, NGSgo® Library Full Kit, and NGSengine® software. The assay is validated through an IVDR clinical performance study. It supports the pivotal phase 3 ARTEMIA clinical trial of Tedopi®, an HLA-restricted epitope-based cancer vaccine, for second-line treatment of NSCLC patients with secondary resistance to Immune Checkpoint Inhibitors (ICI).

➡️ Clinicaltrials.gov: NCT06472245

🔗 Learn more about our CDx services:
https://www.gendx.com/companion-diagnostics/introduction/

🔗 Learn more about Tedopi® and the ARTEMIA trial in our webinar:
https://www.gendx.com/education/on-demand-webinars/

When time is critical, your HLA amplification step should be fast, precise, and simple.
That is exactly what our team had in mind when developing NGSgo®-ProntoAmp.

By combining pre-mixed primers and enzymes, we've simplified the setup; all you need to do is add DNA.

Compatible with both Illumina (via NGSgo® Library Full Kit) and Oxford Nanopore Technologies (via NGS-Pronto®Prep) sequencing platforms.

Learn more about this product on our website:
🔗 https://www.gendx.com/product_line/ngsgo-prontoamp/

hashtag